Biotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics

Shares of Pacific Biosciences of California (PACB) were up 5.1% to $5.34 in premarket trading on Tuesday. The Menlo Park, Calif. company is a manufacturer of sequencing systems.

AMAG Pharmaceuticals (AMAG) shares were down nearly 4% to $21.80. The Waltham, Mass.-based company on Tuesday announced unaudited consolidated financial results for the fourth quarter and full-year 2016. AMAG reported fourth-quarter GAAP revenue of $151.6 million, compared with $108.7 million in the year-ago period. Non-GAAP revenue was  $153 million, compared with $120.6 million a year ago. Adjusted Ebitda was $77.4 million, up 26% year-over-year. Also on Tuesday, AMAG and Endoceutics announced an exclusive license agreement for Intraros (prasterone).

Other biotech stock movers include Global Blood Therapeutics (GBT) , whose shares rose 2.4% to $21. The South San Francisco-based company's lead product candidate is GBT440, which is being developed as a therapy for sickle cell disease.

More from Stocks

Facebook Jumps on $9 Billion Buyback Plan, Bullish Note From Deutsche Bank

Facebook Jumps on $9 Billion Buyback Plan, Bullish Note From Deutsche Bank

Nutrisystem Soars on Deal to Be Acquired by Tivity Health

Nutrisystem Soars on Deal to Be Acquired by Tivity Health

Apple Stock Overcomes Trade Troubles to Post Gain on Monday

Apple Stock Overcomes Trade Troubles to Post Gain on Monday

Economist Perspective: Can U.S. Dollar Keep Its Momentum in 2019?

Economist Perspective: Can U.S. Dollar Keep Its Momentum in 2019?

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts